Read More

Clovis Oncology Announced Rubraca (Rucaparib) as First-Line Maintenance Treatment Improves Progression-Free Survival in Women with Advanced Ovarian Cancer Across Disease Risk Subgroups; Data Presented at ESMO 2022

Clovis Oncology, Inc. (NASDAQ: CLVS), today announced results from a subgroup analysis of data from the monotherapy comparison of the randomized, Phase 3 ATHENA (GOG-3020/ENGOT-ov45) trial (ATHENA-MONO).

CLVS

Read More

Puma Biotechnology Announced Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib for HER2-Mutant, Recurrent/Metastatic Cervical Cancer at the ESMO Congress 2022

Puma Biotechnology, Inc. (NASDAQ: PBYI) announced the presentation of updated findings from the Phase II SUMMIT basket trial of neratinib for HER2 (ERBB2)-mutant, metastatic cervical cancer at the 2022 European Society for Medical Oncology (ESMO) Congress, currently taking place in Paris, France.

PBYI

Read More

Sports Betting Check-Ins Jump 77% For Opening Night: Here’s How Many People Could Bet On 2022 NFL Season

The National Football League kicked off its 2022 season with a marquee Thursday Night Football matchup between the Los Angeles Rams and Buffalo Bills. With more states having legalized sports betting for the season, here’s a look at what could be in store for the industry and publicly traded sports betting companies.

CZR